BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 33293358)

  • 1. Peripheral Myeloid Cell EP2 Activation Contributes to the Deleterious Consequences of Status Epilepticus.
    Varvel NH; Espinosa-Garcia C; Hunter-Chang S; Chen D; Biegel A; Hsieh A; Blackmer-Raynolds L; Ganesh T; Dingledine R
    J Neurosci; 2021 Feb; 41(5):1105-1117. PubMed ID: 33293358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infiltrating monocytes promote brain inflammation and exacerbate neuronal damage after status epilepticus.
    Varvel NH; Neher JJ; Bosch A; Wang W; Ransohoff RM; Miller RJ; Dingledine R
    Proc Natl Acad Sci U S A; 2016 Sep; 113(38):E5665-74. PubMed ID: 27601660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological inhibition of the inflammatory receptor CCR2 relieves the early deleterious consequences of status epilepticus.
    Alemán-Ruiz C; Wang W; Dingledine R; Varvel NH
    Sci Rep; 2023 Apr; 13(1):5651. PubMed ID: 37024553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus.
    Jiang J; Yang MS; Quan Y; Gueorguieva P; Ganesh T; Dingledine R
    Neurobiol Dis; 2015 Apr; 76():126-136. PubMed ID: 25600211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Second-Generation EP2 Receptor Antagonist Reduces Neuroinflammation and Gliosis After Status Epilepticus in Rats.
    Rojas A; Amaradhi R; Banik A; Jiang C; Abreu-Melon J; Wang S; Dingledine R; Ganesh T
    Neurotherapeutics; 2021 Apr; 18(2):1207-1225. PubMed ID: 33410110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation.
    Jiang J; Quan Y; Ganesh T; Pouliot WA; Dudek FE; Dingledine R
    Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3591-6. PubMed ID: 23401547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the prostaglandin EP2 receptor is neuroprotective and accelerates functional recovery in a rat model of organophosphorus induced status epilepticus.
    Rojas A; Ganesh T; Lelutiu N; Gueorguieva P; Dingledine R
    Neuropharmacology; 2015 Jun; 93():15-27. PubMed ID: 25656476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppressing pro-inflammatory prostaglandin signaling attenuates excitotoxicity-associated neuronal inflammation and injury.
    Jiang J; Yu Y; Kinjo ER; Du Y; Nguyen HP; Dingledine R
    Neuropharmacology; 2019 May; 149():149-160. PubMed ID: 30763657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microglia are less pro-inflammatory than myeloid infiltrates in the hippocampus of mice exposed to status epilepticus.
    Vinet J; Vainchtein ID; Spano C; Giordano C; Bordini D; Curia G; Dominici M; Boddeke HW; Eggen BJ; Biagini G
    Glia; 2016 Aug; 64(8):1350-62. PubMed ID: 27246930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of EP
    Yousif NM; de Oliveira ACP; Brioschi S; Huell M; Biber K; Fiebich BL
    Glia; 2018 Apr; 66(4):708-724. PubMed ID: 29226424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of inflammation with conditional deletion of the prostaglandin E2 EP2 receptor in macrophages and brain microglia.
    Johansson JU; Pradhan S; Lokteva LA; Woodling NS; Ko N; Brown HD; Wang Q; Loh C; Cekanaviciute E; Buckwalter M; Manning-Bog AB; Andreasson KI
    J Neurosci; 2013 Oct; 33(40):16016-32. PubMed ID: 24089506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting prostaglandin receptor EP2 for adjunctive treatment of status epilepticus.
    Nagib MM; Yu Y; Jiang J
    Pharmacol Ther; 2020 May; 209():107504. PubMed ID: 32088247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the prostaglandin E2 receptor EP2 prevents status epilepticus-induced deficits in the novel object recognition task in rats.
    Rojas A; Ganesh T; Manji Z; O'neill T; Dingledine R
    Neuropharmacology; 2016 Nov; 110(Pt A):419-430. PubMed ID: 27477533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection of hippocampal neurogenesis from toll-like receptor 4-dependent innate immune activation by ablation of prostaglandin E2 receptor subtype EP1 or EP2.
    Keene CD; Chang R; Stephen C; Nivison M; Nutt SE; Look A; Breyer RM; Horner PJ; Hevner R; Montine TJ
    Am J Pathol; 2009 Jun; 174(6):2300-9. PubMed ID: 19389932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2.
    Jiang J; Ganesh T; Du Y; Quan Y; Serrano G; Qui M; Speigel I; Rojas A; Lelutiu N; Dingledine R
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3149-54. PubMed ID: 22323596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PGE
    Liu Q; Liang X; Wang Q; Wilson EN; Lam R; Wang J; Kong W; Tsai C; Pan T; Larkin PB; Shamloo M; Andreasson KI
    Proc Natl Acad Sci U S A; 2019 May; 116(20):10019-10024. PubMed ID: 31036664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical development of an EP2 antagonist for post-seizure cognitive deficits.
    Varvel NH; Amaradhi R; Espinosa-Garcia C; Duddy S; Franklin R; Banik A; Alemán-Ruiz C; Blackmer-Raynolds L; Wang W; Honore T; Ganesh T; Dingledine R
    Neuropharmacology; 2023 Feb; 224():109356. PubMed ID: 36460083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rat model of organophosphate-induced status epilepticus and the beneficial effects of EP2 receptor inhibition.
    Rojas A; Ganesh T; Wang W; Wang J; Dingledine R
    Neurobiol Dis; 2020 Jan; 133():104399. PubMed ID: 30818067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TrkB-Shc Signaling Protects against Hippocampal Injury Following Status Epilepticus.
    Huang YZ; He XP; Krishnamurthy K; McNamara JO
    J Neurosci; 2019 Jun; 39(23):4624-4630. PubMed ID: 30926745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin E2 EP2 receptor deletion attenuates intracerebral hemorrhage-induced brain injury and improves functional recovery.
    Leclerc JL; Lampert AS; Diller MA; Immergluck JB; Doré S
    ASN Neuro; 2015; 7(2):. PubMed ID: 25873308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.